GTx Inc. (GTXI:US) declined 6.9 percent to $3.62 and slipped as much as 7.5 percent, the most intraday since Nov. 16. The developer of a drug to prevent broken bones in prostate- cancer patients said it will cut 28 percent of its staff after the drug was delayed by the U.S. Food and Drug Administration.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.